Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) is a prevalent, refractory pelvic pain condition characterized by pain in the pelvic area and urinary frequency, largely unresponsive to medical interventions. This study used multiple mediations to test the associations of validated pain appraisal and behavioural coping strategies between pain and quality of life. Patients (N = 175) were recruited from tertiary care urology clinics and completed questionnaires. Exploratory factor analyses were conducted on four individual measures (Chronic Pain Coping Inventory, Survey of Pain Attitudes – Control subscale, Center for Epidemiologic Studies Depression Scale, and Pain Catastrophizing Scale), then on the empirically derived factors that produced four factors to be used in regression and multiple mediation models: illness-focused behavioural coping, catastrophizing, wellness-focused behavioural coping, and depression. In regressions, CP/CPPS patient symptoms (p < .01), illness-focused behavioural coping (p < .01) and wellness-focused behavioural coping (p < .05) predicted physical quality of life, while catastrophizing (p < .01) and illness-focused behavioural coping (p < .05) predicted mental quality of life. Mediation analyses showed that illness-focused behavioural coping strategies partially mediated the relationship between pain and physical quality of life, whereas catastrophizing and illness-focused behavioural coping strategies both fully mediated the relationship between pain and mental quality of life. These results identify catastrophizing and illness-focused coping as key psychosocial targets for interventions for patient quality of life in CP/CPPS. / Thesis (Master, Psychology) -- Queen's University, 2013-08-27 17:07:11.853

Resumo: A Síndrome da Dor Pélvica Crônica (SDPC) é uma nova categoria na classificação atual das prostatites. A causa da SDPC é desconhecida, a teoria mais aceita é o refluxo intraprostático. Não há estudo que comprove qual o melhor tratamento. A finasterida, uma das drogas utilizadas para o tratamento, é um antiandrogênio que bloqueia a enzima 5-alfa redutase, diminuindo o tamanho da próstata. A finasterida agiria na SDPC reduzindo o tecido glandular prostático, diminuindo a tensão intraprostática e conseqüentemente o refluxo intraprostático. Avaliar a efetividade e a segurança da finasterida no tratamento da SDPC. Uma revisão sistemática de ensaios clínicos aleatorizados foi realizada, sem restrições de língua, datas ou outras considerações. As fontes de informação utilizadas foram Medline, Registro de Ensaios Controlados da Cochrane, Embase, Lilacs e SciELO. Contato com autores de artigos, laboratórios que comercializam finasterida e revistas médicas em geral e específicas. Foram incluídos pacientes com diagnóstico da SDPC tipo IIIA e/ou IIIB, participantes de estudos em que foi comparado o uso da finasterida com placebo ou outro tipo de tratamento. Os desfechos clínicos avaliados foram os questionários dos sintomas prostáticos, exames para avaliar a melhora bioquímica ou variável fisiológica e eventos adversos. A coleta de dados e análise foram realizadas por dois revisores que inspecionaram as referências encontradas independentemente pela estratégia de busca e aplicaram os critérios de inclusão nos estudos selecionados usando os critérios de qualidade metodológica descritos no Cochrane handbook. A escala de Jadad e Schutz também foram usadas. Os dados dos estudos elegíveis foram sumarizados em metanálise. A análise estatística foi realizada utilizando o ...(Resumo completo, clicar acesso eletrônico abaixo) / Abstract: Chronic Pelvic Pain Syndrome (CPPS) is a new category in the current classification of prostatitis. The cause of CPPS is unknown; the most accepted theory is intraprostatic ductal reflux. The best treatment is not known. Finasteride, a specific type II 5a-reductase inhibitor, decreases the size of the prostate. A potential mechanism of action for finasteride is the reduction of the intraprostatic tension due to the glandular shrinkage, decreasing the intraprostatic ductal reflux. To assess the effectiveness and harms of finasteride in the treatment of CPPS. A systematic review of randomized controlled trials was performed, with no restrictions on language, dates or other considerations. The information sources used were Medline, the Cochrane Central Register of Controlled Trials, Embase, Lilacs and SciELO; contact authors of articles, laboratories that work with finasteride and general and specific medical magazines. It included participants with a diagnosis of CPPS type IIIA and/or IIIB taking part of studies comparing the use of finasteride to placebo or another type of treatment. The clinical outcomes evaluated were the questionnaires of prostatic symptoms, improvement in biochemical or physiologic variables and adverse events. The collecting data and analysis were performed by two reviewers that checked the found references independently by the search strategy, and applied the inclusion criteria in the selected studies using the criteria of methodological quality described on Cochrane Handbook. The Jadad and the Schutz scales were also used. After finding all eligible studies, the data were summarized in meta-analysis. The statistical analysis was undertaken using the MetaView statistical program within Review Manager software of the Cochrane Collaboration. Three studies with 181 patients were included. The length ...(Complete abstract click electronic access below) / Orientador: Antônio José Maria Catâneo / Coorientador: Paulo Eduardo de Oliveira Carvalho / Banca: Tânia Ruiz / Banca: Bernardo Garcia de Oliveira Soares / Mestre

Made available in DSpace on 2014-06-11T19:25:19Z (GMT). No. of bitstreams: 0 Previous issue date: 2008-05-09Bitstream added on 2014-06-13T18:53:13Z : No. of bitstreams: 1 chambo_rc_me_botfm.pdf: 605131 bytes, checksum: 81f0a6d5dda1782f51f5b580a20f8761 (MD5) / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) / A Síndrome da Dor Pélvica Crônica (SDPC) é uma nova categoria na classificação atual das prostatites. A causa da SDPC é desconhecida, a teoria mais aceita é o refluxo intraprostático. Não há estudo que comprove qual o melhor tratamento. A finasterida, uma das drogas utilizadas para o tratamento, é um antiandrogênio que bloqueia a enzima 5-alfa redutase, diminuindo o tamanho da próstata. A finasterida agiria na SDPC reduzindo o tecido glandular prostático, diminuindo a tensão intraprostática e conseqüentemente o refluxo intraprostático. Avaliar a efetividade e a segurança da finasterida no tratamento da SDPC. Uma revisão sistemática de ensaios clínicos aleatorizados foi realizada, sem restrições de língua, datas ou outras considerações. As fontes de informação utilizadas foram Medline, Registro de Ensaios Controlados da Cochrane, Embase, Lilacs e SciELO. Contato com autores de artigos, laboratórios que comercializam finasterida e revistas médicas em geral e específicas. Foram incluídos pacientes com diagnóstico da SDPC tipo IIIA e/ou IIIB, participantes de estudos em que foi comparado o uso da finasterida com placebo ou outro tipo de tratamento. Os desfechos clínicos avaliados foram os questionários dos sintomas prostáticos, exames para avaliar a melhora bioquímica ou variável fisiológica e eventos adversos. A coleta de dados e análise foram realizadas por dois revisores que inspecionaram as referências encontradas independentemente pela estratégia de busca e aplicaram os critérios de inclusão nos estudos selecionados usando os critérios de qualidade metodológica descritos no Cochrane handbook. A escala de Jadad e Schutz também foram usadas. Os dados dos estudos elegíveis foram sumarizados em metanálise. A análise estatística foi realizada utilizando o... / Chronic Pelvic Pain Syndrome (CPPS) is a new category in the current classification of prostatitis. The cause of CPPS is unknown; the most accepted theory is intraprostatic ductal reflux. The best treatment is not known. Finasteride, a specific type II 5a-reductase inhibitor, decreases the size of the prostate. A potential mechanism of action for finasteride is the reduction of the intraprostatic tension due to the glandular shrinkage, decreasing the intraprostatic ductal reflux. To assess the effectiveness and harms of finasteride in the treatment of CPPS. A systematic review of randomized controlled trials was performed, with no restrictions on language, dates or other considerations. The information sources used were Medline, the Cochrane Central Register of Controlled Trials, Embase, Lilacs and SciELO; contact authors of articles, laboratories that work with finasteride and general and specific medical magazines. It included participants with a diagnosis of CPPS type IIIA and/or IIIB taking part of studies comparing the use of finasteride to placebo or another type of treatment. The clinical outcomes evaluated were the questionnaires of prostatic symptoms, improvement in biochemical or physiologic variables and adverse events. The collecting data and analysis were performed by two reviewers that checked the found references independently by the search strategy, and applied the inclusion criteria in the selected studies using the criteria of methodological quality described on Cochrane Handbook. The Jadad and the Schutz scales were also used. After finding all eligible studies, the data were summarized in meta-analysis. The statistical analysis was undertaken using the MetaView statistical program within Review Manager software of the Cochrane Collaboration. Three studies with 181 patients were included. The length ...(Complete abstract click electronic access below)

Excerpt: To the editor: The authors of the article on chronic prostatitis effectively summarize the practical dilemmas that arise when managing this complex disease.

Chronic pelvic pain is a condition which receives less attention in men than in women. It is often difficult to diagnose and more difficult to treat. The new classification of prostatitis and its variants has introduced the term ‘chronic pelvic pain syndrome’ which underlines the difficulties in dealing with this disorder which may represent a variety of chronically painful conditions with a large functional component. / Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.

Abstract The principal aim of a population-based cross-sectional survey was to generate information on the lifetime occurrence of prostatitis in Finnish men and their exposure to the disease, and also on the influence of prostatitis-related fears and disturbances on their sexual life. A second aim was to develop and clinically validate a new diagnostic tool for differential diagnosis between the forms of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), especially between patients belonging to categories IIIA and IIIB in the new NIH (National Institutes of Health) clinical classification. Altogether 1832 men out of 2500 aged 20–59 years chosen randomly from the two most northerly provinces of Finland (Oulu and Lapland) participated in the epidemiological study, a response rate of 75%. The overall lifetime prevalence of prostatitis was 14.2%. The risk of having had the disease increased with age, being 1.7 times greater in the men aged 40–49 years than in those aged 20–39 years, and 3.1 times greater in those aged 50–59 years. More than a quarter of the 261 men who had or had had prostatitis symptoms (27%) suffered from them at least once a year, while 16% suffered from chronic prostatitis symptoms throughout the year. 63% of the men with prostatitis had their worst symptoms during the wintertime (November–march). 17% of the men with chronic prostatitis reported a constant fear of undetected prostate cancer. Erectile dysfunction was reported by 43% of the symptomatic men and decreased libido by 24%. Self-assessment of personality showed that the men with prostatitis were more often busy and nervous and had a meticulous attitude to life and problems than were the non-symptomatic men. 197 patients with chronic prostatitis/chronic pelvic pain syndrome participated in three clinical case-control studies during the years 1995–2000, at Oulu University Hospital, the District Hospital of Oulainen and Seinäjoki Central Hospital. The first prostatic tissue pressure measurement (PTPM) study included 34 patients and 9 controls. A novel method was developed to measure intraprostatic tissue pressure with a Stryker® intracompartmental pressure monitor. The PTPM showed a clear increase (p &lt; 0.001) in the patients with symptoms of prostatitis and benign prostatic enlargement (BPE) relative to the controls and the patients with BPE but without pain symptoms. The second PTPM study included 42 patients with chronic prostatitis symptoms without significant BPE and 12 new controls. Significantly higher pressure readings (p &lt; 0.001) were recorded at all three measurement points in the patients than in the controls. 48 new patients and 12 new controls were enrolled for the third PTPM study, the purpose of which was to confirm the results of the previous ones and to compare the prostatic tissue pressures of two clinical groups (IIIA and IIIB). The prostatic tissue pressure was again significantly higher in the patients with chronic prostatitis symptoms than in the controls (p &lt; 0.001). An interesting finding was that prostatitis patients belonging to clinical category IIIA had significantly higher tissue pressures (p &lt; 0.01) than those in category IIIB, probably reflecting more severe inflammation in the prostatic tissue. This new PTPM method provides a more precise and/or exact tool for differential diagnosis between the forms of pelvic pain and CP/CPPS.

Chronic pelvic pain is a condition which receives less attention in men than in women. It is often difficult to diagnose and more difficult to treat. The new classification of prostatitis and its variants has introduced the term ‘chronic pelvic pain syndrome’ which underlines the difficulties in dealing with this disorder which may represent a variety of chronically painful conditions with a large functional component. / Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.